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Abstract
Multimorbidity is a common and burdensome condition that may affect quality of life, increase medical needs, and make people live more 
years of life with disability. Negative outcomes related to multimorbidity occur beyond what we would expect from the summed effect of 
single conditions, as chronic diseases interact with each other, mutually enhancing their negative effects, and eventually leading to new clinical 
phenotypes. Moreover, multimorbidity mirrors an accelerated global susceptibility and a loss of resilience, which are both hallmarks of aging. 
Due to the complexity of its assessment and definition, and the lack of clear evidence steering its management, multimorbidity represents one 
of the main current challenges for clinicians, researchers, and policymakers. The authors of this article recently reflected on these issues during 
two twin international symposia at the 2016 European Union Geriatric Medicine Society (EUGMS) meeting in Lisbon, Portugal, and the 2016 
Gerontological Society of America (GSA) meeting in New Orleans, USA. The present work summarizes the most relevant aspects related to 
multimorbidity, with the ultimate goal to identify knowledge gaps and suggest future directions to approach this condition.
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Multimorbidity, defined as the co-occurrence of multiple diseases 
in one same person, affects a large proportion of older people 
and represents a distinctive hallmark of aging (1,2). Aging and 
chronic diseases fuel one another in a vicious circle, each accel-
erating the progression of the other (3–5). Further, aging with 
multimorbidity means experiencing a poorer quality of life, hav-
ing higher medical needs and spending more years of life with 
disability (1). Negative outcomes related to multimorbidity occur 
beyond what we would expect from the summed effect of sin-
gle conditions, as chronic diseases interact with each other lead-
ing to enhanced negative effects, and eventually to new clinical 
phenotypes (eg, geriatric syndromes) (6,7). Health practitioners 
strive to provide adequate care to seniors with multimorbidity, 
but their actions are hampered by traditional clinical constructs 
based on a reductionist single-disease view of medicine. Such 
constructs collide with the widely advocated holistic approach 
to older people’s health, where not only diseases but also non-
nosological conditions and the environment may lead to a state 
of frailty (8,9). Due to the complexity of its assessment and defi-
nition, and the lack of clear evidence steering its management, 
multimorbidity represents today one of the major challenges for 
clinicians, researchers and policymakers (8,10).
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The authors of this article recently reflected on these issues during 
two twin international symposia at the 2016 European Union Geriatric 
Medicine Society (EUGMS) meeting in Lisbon, Portugal, and the 2016 
Gerontological Society of America (GSA) meeting in New Orleans, 
USA. In the present work, we summarize the most relevant aspects 
discussed during these two events, with the ultimate goal to identify 
knowledge gaps and suggest future directions to approach multimor-
bidity: the big elephant in the room of our health care systems.
Epidemiology of Multimorbidity: Some 
Methodological Considerations
With a prevalence spanning from 55% to 98%, multimorbidity is 
the most common feature characterizing older adults (Figure 1) (1). 
Older age, female sex, and low socioeconomic status are the strongest 
determinants of multimorbidity. Living in deprived areas may antici-
pate the onset of multimorbidity by 10–15 years (8). Still, variability 
in the prevalence of multimorbidity is not entirely explained by the 
sociodemographic profile. Being able to adequately operationalize the 
measurement of multimorbidity in the population represents the basis 
to fine-tune guidelines and care models to people with multimorbidity. 
However, results are vitiated by: (i) the lack of a universal definition 
of chronic disease (11); (ii) the use of heterogeneous lists of chronic 
diseases, ranging from few to more than a hundred different nosologi-
cal entities (12); (iii) the aggregation of diseases according to differ-
ent levels of specificity; and (iv) the use of different cutoffs for the 
definition of multimorbidity (11). Recently, in an attempt to face the 
above-mentioned limitations, a proposal for the operationalization of 
multimorbidity in older people was suggested by Calderón-Larrañaga 
and colleagues (11). In this work, 918 chronic diseases (coded using 
the International Classification of Diseases [ICD] 10th revision) were 
identified and grouped into 60 homogeneous categories by an inter-
national team of geriatricians and general practitioners. Once widely 
validated, this tool could provide the common language needed for 
comparisons across different countries, settings, and research groups.
There is consistent evidence that chronic diseases tend to aggre-
gate in one same individual according to specific patterns (13). 
So far, many clusters of chronic diseases have been identified, and 
those with highest consistency across the literature include cardio-
metabolic, neuropsychiatric, and musculoskeletal disorders. Shared 
pathophysiological pathways and risk factors partially explain the 
systematic clustering of diseases. However, several associations still 
remain unexplained, raising question about the consistency of the 
associations itself. Studying how and why diseases appear together 
might help to detect homogeneous groups of people sharing analo-
gous needs, prognosis and health trajectories. This could eventually 
contribute to improve the effectiveness of our models of care and 
better tailoring interventions for complex older adults (13,14).
Are Health Care Systems Ready to Deal With 
Multimorbidity?
Although multimorbidity is one of the strongest predictors of health 
care services utilization (Figure 2a), the capacity of many health care 
systems to address frail patients affected by multiple diseases still lacks 
consistency and is often not rooted on scientific knowledge (15). As a 
consequence, in spite of a continued increase in health care spending, 
the auspicated changes for better addressing the clinical needs as well 
as improving patients’ satisfaction and quality of life are still unat-
tended. Underlying this disconnection is a triadic crisis overarching 
health systems, medicine, and health professionals (16). Health sys-
tems are still designed to address acute health problems, even if older 
people’s health and social needs tend to span over a spectrum of areas 
of functioning and to wax and wane over time. Modern medicine pri-
oritizes technology and hyper-specialization, and the emphasis on a 
strong primary and highly coordinated care, which is needed more 
Figure 1. Number of chronic diseases by age groups in the Swedish National 
Study on Aging and Care in Kungsholmen (SNAC-K; N = 3,363).
Figure 2. Association of the number of chronic diseases with (a) number 
of drugs and (b) number of different providers involved in the care process 
of older people from the Swedish National Study on Aging and Care in 
Kungsholmen (SNAC-K; N = 3,363).
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than ever before, is progressively fading. Last, while many physicians 
recognize that effective care of older persons affected by multiple dis-
eases and interacting social and financial constrains requires a “whole 
human” approach, the distance between health professionals and 
patients seems to gradually widen. All of this has led to health care 
models that are often expensive, burdensome, of unclear benefit and 
potential harm, and economically unsustainable (17).
Changes are needed. First, quality and performance measurements 
should be developed and implemented. They should not be merely 
focused on the cure of specific diseases but primarily capture the indi-
vidual’s functions in order to prioritize care preferences and provide 
added value to treatments and interventions (18). With this regard, 
the multidimensional assessment of multimorbid patients may help to 
detect social, psychological, and environmental factors that are crucial 
determinants of the effectiveness of care. Second, innovations in health 
care delivery should guarantee integration and coordination across 
different clinicians and care settings (19). Ensuring that each patient 
has a clearly designated primary care doctor and nurse is critical for 
care continuity (20). Third, since in the presence of multimorbidity 
(and especially when associated with frailty), most medical decisions 
are not supported by robust scientific evidence, it is imperative that 
physicians share the decision-making process with their patients, 
incorporating their values and priorities in the care plan (21). Fourth, 
the identification and treatment of symptoms and diseases upon which 
medical education and training is exclusively based should be com-
plemented with other nonmedical processes, such as shared decision-
making, team-based care, and/or use of information technology (22). 
Last, patients and citizens need to become familiar with the concepts 
of priorities and tradeoffs, understand the balance between harms and 
benefits of interventions, and be willing to participate in shared deci-
sion making (23).
Clinical Guidelines for the Management of 
Multimorbidity
In the past few years, a number of articles have highlighted that dis-
ease-specific guidelines are difficult to apply in patients affected by 
multiple chronic diseases, making their effectiveness questionable 
(19,24,25). The reasons for such discrepancy rely on both the way 
disease-specific guidelines are developed and their applicability in 
real life. First, disease-specific guidelines are usually based on find-
ings from randomized clinical trials that have systematically excluded 
frail persons affected by multiple coexisting diseases (26). Second, few 
guidelines acknowledge that target patients can also suffer from other 
diseases for which they might also receive additional medications (27).
Recently, there have been attempts to develop guidelines for per-
sons affected by multimorbidity, some of them are summarized in 
Table 1. It is noteworthy that the primary goal of such guidelines 
is no longer to increase survival or to accomplish a disease-specific 
target (eg, lowering cholesterol or blood pressure values), but rather 
to maximize quality of life. These principles are aimed at health care 
professionals, patients with multimorbidity, and their caregivers, and 
have the potential for high external validity.
Despite having been elaborated by two different groups of 
experts, the two most recent guidelines issued by the NICE and the 
JA-CHRODIS present several commonalities (28,29). First, they 
make a serious attempt to identify people who might benefit from 
their application, for example, frail individuals. Second, they sup-
port the flexible use of disease-specific guidelines with special focus 
on treatment burden. Third, both emphasize the need to assure care 
coordination and the identification of a health care provider that is 
responsible for patients’ global care process. Fourth, they encour-
age shared decision making to agree on an individualized care plan. 
Table 1. Examples of Guidelines and Recommendations for the Care of People with Multimorbidity
Guidelines, Year Description
Guiding principles for the care of older adults with 
multimorbidity, 2012 (23)
Consensus document by the American Geriatrics Society (AGS) Expert Panel on the Care of 
Older Adults with Multimorbidity.
It offers expert-based guidance on patient preferences, interpreting the evidence, prognosis, 
clinical feasibility, and optimizing therapies and care plans.
The principles are relevant across settings and types of clinicians.
Managing multiple chronic conditions (MCC): a  
strategic framework for improving health outcomes  
and quality of life, 2011 (53)
Action-oriented framework developed by the U.S. Department of Health and Human Services.
One of its goals is to provide better tools and information to health care, public health, and 
social services workers who deliver care to individuals with MCC.
It includes key objectives and strategies that can be used to address MCC.
Minimally Disruptive Medicine Care Model for 
patients with multiple chronic conditions, 2015 (54)
Theory-based approach to care that focuses on achieving patient goals for life and health 
while imposing the smallest possible treatment burden on patients’ lives.
It focuses on how to identify the right care; and how to make it happen.
Ariadne principles to handle multimorbidity  
in primary care consultations, 2014 (55)
Guiding principles aimed at sharing realistic treatment goals by physicians and patients in 
primary care.
The principles result from: (i) an interaction assessment of the patient’s health and context; (ii) the 
prioritization of health problems taking into account patient preferences; and (iii) individualized 
management considering the best options of diagnostics, treatment, and prevention.
Guideline for the comprehensive clinical care of 
multimorbid chronic patients, 2017 (29)
Elaborated by the Joint Action on CHROnic DISeases and promoting healthy ageing across 
the life cycle (JA-CHRODIS) funded by the European Commission.
The overall aim is to describe sixteen key components for an optimum care model for 
multimorbid patients.
Guideline for the clinical assessment and management  
of multimorbidity, 2016 (28)
Elaborated by the National Institutet of Health and Care Excellence (NICE).
It aims to improve quality of life by promoting shared decisions based on what is important 
to each person in terms of treatments, health priorities, lifestyle, and goals.
It is targeted to people with multimorbidity, their families, and caregivers.
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Fifth, both provide recommendations for patients and families to 
improve self-management and self-efficacy.
Challenges in the Field of Pharmacological 
Treatment
The presence of multimorbidity presents numerous therapeutic chal-
lenges (30). The pharmacological treatment of multiple chronic condi-
tions often determines polypharmacy (Figure 2b) and increased risk of 
iatrogenic illness (25). The direct application of disease-specific guide-
lines in persons with multimorbidity leads to several drug-disease inter-
actions (27). Indeed, the effect of a medication for a given condition 
might be substantially different when observed in an individual only 
with that disease compared to a frail one characterized by multimorbid-
ity (31). The involvement of clinical pharmacists and the use of technol-
ogies (eg, computerized prescription support systems) in the medication 
review of multimorbid and frail older adults might be useful for improv-
ing the quality of the prescribing process (32). The effectiveness of phy-
sician training on prescription appropriateness and shared decision 
making is also being tested in two ongoing European trials (33,34).
Patients with multimorbidity usually present higher levels of com-
plexity and consequent increased risk of iatrogenic events due to func-
tional, cognitive and social problems as well as the presence of geriatric 
syndromes (eg, urinary incontinence, delirium, falls) (35). Moreover, 
these patients may not properly adhere to treatment protocols, with 
the risk of incurring in errors that may cause harm (eg, antihyper-
tensive treatment and orthostatic hypotension) and/or function loss 
(eg, cognitive impairment due to anticholinergic drugs). In order to 
improve the appropriateness of treatments, all the elements potentially 
affecting effectiveness and adherence should be timely identified and 
weighted during the prescription process. In this regard, the compre-
hensive geriatric assessment might help to draw a clinical, functional 
and social profile of complex patients that can help in the prioritiza-
tion of specific areas of intervention (36). When potential harms of a 
treatment outweigh its benefits, especially in the context of frailty and 
social disadvantages, medication deprescribing should be considered 
in order to improve quality of life and reduce treatment burden (37).
Multimorbidity and Frailty: Two Complementary 
Measures of Biological Aging
For decades, geriatric medicine has constantly been looking for 
useful and reliable models able to help: (i) clinicians, to better pre-
dict the prognosis of complex patients and tailor more appropriate 
treatments; (ii) researchers, to properly understand the mechanisms 
underlying the aging process; and (iii) health systems, to effectively 
address the needs and optimize the care of complex older adults. 
Frailty together with multimorbidity are emerging as promising 
biomarkers of aging. Although closely related, these two constructs 
have rarely been investigated together (38).
Frailty is defined as a medical syndrome with multiple causes and 
contributors that is characterized by diminished strength, endurance, 
and reduced physiologic function, increasing an individual’s vulner-
ability to dependency and/or death (39). This construct is intended 
to capture both clinical and subclinical deficits that accumulate dur-
ing the aging process, and it may represent a proxy measure of the 
biological health of the individual. Frailty well discriminates people 
with higher versus lower risk of adverse events and is a potentially 
powerful tool for assessing complexity and prognosis (40).
Under this perspective, frailty and multimorbidity largely overlap. In 
fact, multimorbidity might be considered as the accumulation of biolog-
ical abnormalities that are clinically relevant and define disease diagno-
ses (35,41). The rapid accumulation of chronic diseases may accelerate 
the development of frailty and vice versa (5). Disease-related inflam-
mation has been suggested as the process shared by multimorbidity 
and frailty (2). If inflammation is a causal element or only a proxy for 
unmeasurable biological dysfunctions remains to be clarified. Indeed, 
an important accumulation of damage can occur below the threshold 
of disease definition, or in domains currently not counted as diseases. 
With this regard, frailty is able to capture multiple biological and func-
tional deficits regardless of clinical thresholds or the severity of diseases 
themselves, usually not accounted for in most multimorbidity measures.
Although frailty and multimorbidity are overlapping and com-
plementary concepts, they remain separate entities since patients 
with multimorbidity may or may not be frail, and vice versa. Frailty 
might be used to distinguish patients with multimorbidity that could 
benefit from traditional treatment from those who might better ben-
efit from a comprehensive and integrated intervention (28). Given 
their increased vulnerability, patients with multimorbidity and frailty 
could respond negatively to a rigid guidelines-based treatment and, 
for these patients, the development of an individualized care plan 
might be recommended (28). On the other hand, patients with mul-
timorbidity but without frailty are more similar to those included in 
randomized clinical trials, making the application of clinical guide-
lines more reasonable in this population.
Even if both concepts adequately describe the consequences of 
the aging process and are useful predictors of negative outcomes, 
none of them is free from limitations (Figure 3), raising the need for 
further empirical investigations: how can these constructs be incor-
porated into routine clinical practice in order to improve the care 
of older adults? Can they be combined in order to maximize their 
clinical and epidemiological applicability?
Figure 3. Multimorbidity and frailty: two constructs with close relationship, similar consequences and equal challenges.
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Discussion
Identified gaps and suggested future perspectives are summarized in 
Table 2. Standardization is a first mandatory step: we need univocal 
ways to measure and collect data on multimorbidity. The advantage 
when it comes to diseases is that these are routinely collected during 
clinical practice, allowing researchers to study the epidemiology 
of multimorbidity in real world-settings (eg, primary care) (7,42). 
However, structural differences concerning disease-coding systems, 
the idiosyncrasy of electronic health record use and availability, and/
or the potential for among health care-level data integration still 
Table 2. Knowledge Gaps and Future Perspectives in the Study of Multimorbidity
Knowledge Gaps Future Perspectives
RESEARCH
 Standardization
  The lack of standardization in the assessment of  
multimorbidity leads to incomparable and sometimes 
contrasting results.
A clinically-driven prespecified list of chronic conditions needs to be agreed upon 
in order to guarantee comparable assessments of multimorbidity across different 
countries, settings and research groups.
Considering their prevalence and clinical/functional impact in the population, 
geriatric symptoms and syndromes must be part of the definition of multimorbidity.
The use of a cutoff to define multimorbidity has low discriminative power in older 
adults; studying it as a continuous grading scale of medical health problems or as 
clusters of chronic diseases should be further explored.
 Longitudinal approach
  People age at varying speed which may lead to different 
trajectories of disease development. In addition, risk and 
protective factors of multimorbidity have a life-long impact.
Longitudinal studies are required to detect differences in the speed of disease 
accumulation, as a biomarker of the progression of biological aging.
Life-long observations may help identify environmental, behavioral and biological 
determinants of trajectories of multimorbidity development.
Cellular and molecular pathways stemming from the aging process and responsible 
for the development of age-related chronic diseases need to be untangled in order to 
consider new therapeutic targets to prevent the development of multimorbidity.
 Link with frailty
  Multimorbidity and frailty emerge as two complementary 
biomarkers of aging.
The chronological relationship between multimorbidity and frailty should be further 
investigated.
The pooled significance of multimorbidity and frailty for screening, risk stratification 
and prognosis in older adults should be addressed in dedicated studies.
CLINICAL PRACTICE
 Management of multimorbid patients
  Guidelines for the treatment of chronic diseases rely on  
clinical trials excluding complex multimorbid patients.
Albeit recent attempts to issue guidelines for the assessment and management of 
persons with multimorbidity, more initiatives are required to provide practitioners 
with reliable and effective guidance.
Pragmatic randomized controlled trials and qualitative studies need to be performed 
to test the applicability and effectiveness of the guidelines in real-world practice.
 Pharmacological treatment
  The lack of guidelines generates uncertainty regarding  
the safety and effectiveness of prescriptions to  
multimorbid patients.
Computerized prescription support systems are essential to identify potential drug– 
drug and drug–disease interactions, improve prescribing and reduce adverse drug 
reactions.
Factors influencing the treatment’s effectiveness must be promptly identified to 
guarantee the development of personalized regimes that balance benefits and harms.
Patients should be actively involved in the decisions affecting their treatment, 
discussing goals and prioritizing interventions.
HEALTH POLICY AND PUBLIC HEALTH
 Health services organization
  Older people’s health care needs are not met by current  
medical and social care services.
The organization of primary care needs to adapt to the reality of patients with 
multimorbidity, in terms of human resources, information technology, physician 
performance assessment and financial incentives.
The coordination across conditions and between care providers should be facilitated, 
as well as the continuity of care by the physician having the primary responsibility for 
helping multimorbid patients make decisions.
Such interventions need to be assessed through large scale pragmatic cluster 
randomized trials, including detailed process evaluation and cost-effectiveness analyses, 
and using outcome measures that are relevant for patients and their caregivers.
 Prevention of multimorbidity
  There is substantial lack of evidence regarding effective 
measures to prevent multimorbidity.
The design of nonpharmacological trials based on behavioral and multidomain 
interventions in adults and older persons aimed at preventing multimorbidity might 
pave the way to implement effective policies to reduce the burden of chronic diseases.
 Public awareness
  Patients, their relatives and caregivers are familiar with  
single and common diseases as diabetes and hypertension  
but not with multimorbidity.
Making patients and their families aware of the definition, consequences and 
challenges of multimorbidity may facilitate guideline implementation, care 
coordination, and promote self-management in patients themselves.
Primary care physicians and geriatricians, ideally prepared to deal with multimorbid 
patients and their families, are pivotal in this process and should be involved in the 
translation of research to practice.
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hinder comparability. Until a common language is agreed upon, it 
will be difficult to draw conclusions regarding how and for whom 
multimorbidity should be incorporated into clinical decision making 
for screening and prognostic purposes (11). Moreover, the use of a 
cutoff (eg, 2+ diseases) for the definition of multimorbidity has lit-
tle discriminative power in older adults, encompassing people with 
highly varying levels of health status (43). Even more challenging 
might be the assessment and management of multimorbidity in low-
income countries and rural areas, where the poor development and 
limited access to health services strongly affects the validity of the 
concept of disease itself. Similarly but in the opposite direction, over-
medicalization and excessive recourse to diagnostic tests, more fre-
quent in high-income countries, could derive in a clinically irrelevant 
phenomenon underlying multimorbidity.
Another important step forward is the study of multimorbidity 
across long observation periods. The description of multimorbidity 
trajectories depending of older people's disease accumulation rate 
could shed light on the mechanisms of accelerated aging supporting 
the design of future preventive interventions (5,14). In parallel, the 
study of cellular and molecular senescence (ie, geroscience) could 
help researchers detect new targets for therapeutic interventions to 
delay the development of chronic diseases and multimorbidity (44). 
Under this perspective, multidomain intervention trials aimed at pre-
venting multimorbidity and its consequences are warmly encouraged 
(45). Interestingly, the Targeting Aging with Metformin (TAME) 
trial, the first randomized clinical trial testing a drug to slow the 
aging process, will consider the occurrence of several age-related dis-
eases as the primary endpoint (46).
Multimorbidity generates uncertainty at different levels during 
the care process, from care planning to goal definition and therapeu-
tic strategies. This is particularly true in the presence of frailty and/or 
social and environmental disadvantages. The guidelines recently issued 
for the management of multimorbid patients provide, for the first time, 
a framework for the assessment and treatment of multimorbid com-
plex persons, moving the focus from the disease to the patient (28,47). 
However, the feasibility and effectiveness of the implementation of these 
guidelines need to be tested through mixed methodologies. Another 
work package of the JA-CHRODIS has precisely the aim of designing 
pragmatic trials to test the guidelines in real-world conditions (48).
The reorganization and reinforcement of primary care represents 
a key step to optimize resource utilization and to reduce the burden 
exerted by multimorbidity on the patient. Nowadays, care delivered 
to people with multimorbidity generates multiple specialist referrals, 
frequent emergency room and hospital admissions, and invasive (and 
often inappropriate) diagnostic procedures (49–51). This represents 
a source of stress per se affecting, ultimately, patients’ quality of life.
Finally, patients and their families should be informed of the 
consequences and challenges posed by multimorbidity (52). Patient 
empowerment is pivotal in the implementation of coordinated health 
plans, and even more so in contexts where the risk of care fragmenta-
tion is high. This can be accomplished by strengthening their self-man-
agement and self-efficacy, such as through explaining their diagnoses, 
diseases, and medical conditions, as well as by providing information 
on medication use. In turn, patients may learn to use medical devices, 
supportive aids, and health monitoring tools correctly. This might 
also facilitate multimorbidity guideline implementation and help in 
achieving a fully shared decision-making process. Furthermore, pub-
lic health policies aimed at raising population awareness may also aid 
in implementation. Yet, well-prepared primary care physicians and 
nurses are key communicators, particularly in reaching older adults 
affected by multimorbidity and their families.
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